Effect of Escherichia Coli 5C (Colipral®) on Post-Colonoscopy Gastrointestinal Symptoms

Inclusion Criteria: * Age between 18 and 80 years * Complete diagnostic colonoscopy with achievement of the cecal fundus * Accepted written informed consent for study participation obtained prior to the start of the study Exclusion Criteria: * Chronic inflammatory bowel disease * Complicated Diverticular Disease (DICA \>3) * Suspected or known colorectal malignancy on index colonoscopy * Diagnosed microscopic colitis * Operative colonoscopy * Severe chronic gastrointestinal symptoms judged by the investigator to interfere with the evaluation of study endpoints * Subjects who are immunosuppressed or on systemic immunosuppressive treatment, including patients with primary or acquired immunodeficiency, oncological disease on active treatment with chemotherapy/immunotherapy, or autoimmune diseases on immunosuppressive treatment * Taking probiotics, prebiotics, or synbiotics within 2-4 weeks prior to enrollment * Antibiotic therapy within 4 weeks prior to enrollment * Lack of acceptance of written informed consent